Skip To Main Content
Aditya Bardia on Muck Rack

Aditya Bardia

As seen in: Nature, The Oncologist, MDPI, JAMA (The Journal of the American Medical Association), JAMA Oncology, Medscape, The Lancet, HemOnc Today, NewsBreak, AACR Journal and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Aditya

Contact Aditya, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Actionable genetic landscape and dynamics in circulating DNA from 12,827 patients with metastatic breast cancer

|
By Ignaty Leshchiner, Arielle Medford, Justin Cha, Lesli A Kiedrowski, Andrzej Niemierko, Jennifer Keenan, Charles Dai, Laura M. Spring, Beverly Moy, Seth A. Wander, Neelima Vidula, Steven J Isakoff, Dejan Juric, Mendy Miller, Andrew Davis, Lorenzo Gerratana, Ami Shah, Ben Park, Adam Brufsky, Joyce O’Shaughnessy, Rebecca Nagy, Leif W. Ellisen, Massimo Cristofanilli, Aditya Bardia, Gad Getz
| Nature Verified
Abstract Plasma cell-free DNA (cfDNA) is a sensitive, noninvasive tool for monitoring the genomic landscape, heterogeneity, and evolution of cancer, aggregating genetic information from multiple metastatic sites. Here, we study 15,564 cfDNA samples from 12,827 patients with metastatic breast cancer (MBC). We classify samples, deep-sequenced with Guardant360, into MBC subtypes using our trained random forest model.
Open in Who Shared Issue with article?

Genomic biomarkers of ipatasertib response in patients with hormone receptor-positive metastatic breast cancer

|
By Maxwell R. Lloyd, Zahra Bagheri, Elizabeth Scott, Geoffrey G Fell, Lianne Ryan, Jennifer Keenan, Andrzej Niemierko, Laura M. Spring, Jennifer Shin, Steven J Isakoff, Beverly Moy, Elizabeth Fisher, Amber Newton, Lauren Scarpetti, Andreas Varkaris, Leif W. Ellisen, Taronish D. Dubash, Parasvi S. Patel, Ferran Fece de la Cruz, Douglas S. Micalizzi, Shyamala Maheswaran, Daniel A. Haber, Dejan Juric, Aditya Bardia, Seth A. Wander, Sarah Padden, Karleen R. Habin, Elene T. Viscosi-Spieler, Dante Che
| Nature Verified
Abstract AKT inhibitor biomarkers remain undefined in metastatic breast cancer (MBC). The phase Ib TAKTIC trial evaluated ipatasertib with endocrine therapy, or with fulvestrant plus palbociclib, in endocrine-resistant HR + /HER2- MBC. Exploratory baseline ± post-progression circulating-tumor DNA (ctDNA) was analyzed for genomic alterations associated with outcomes. Progression-free survival (PFS) was assessed using Kaplan-Meier and Cox modeling.
Open in Who Shared Issue with article?

Progression-Free Survival in Metastatic Breast Cancer by Local Investigators vs Blinded Independent Central Review : A Systematic Review and Meta-Analysis

|
By Zahra Bagheri, Kevin Kalinsky, Harold J. Burstein, Aditya Bardia, Jason A. Mouabbi, Ruth O’Regan, Seth A. Wander, Lis Victoria Ravani
| JAMA Oncology Verified
Key Points Question Is there a difference in progression-free survival (PFS) estimates when assessed by blinded independent central review (BICR) vs local investigator assessment in randomized clinical trials of hormone receptor–positive/ERBB2-negative metastatic breast cancer?
Open in Who Shared Issue with article?
See all 105 licensed articles (227 Total)